Nanoscale Medical Technology, often referred to as Nanomedicine, can be globally defined as the application of nanotechnology to the clinical domain. While nanoscale materials come in many forms, they all possess a set of unique characteristics otherwise absent at a macroscopic level.
Nanomedicine has a multidisciplinary nature, with many of its attributes deriving from biology, chemistry, and physics. As a result of this successful marriage, nanoscale materials display functions and properties that have exceptional benefits when applied to clinical procedures and medical devices.
The potent chemotherapeutic agents currently used in the treatment of lung cancer cause considerable destruction to normal cells, severe adverse reactions, and unpleasant side effects. With properties not available from either molecular or macroscopic agents, Graphene oxide nanoparticles can deliver these agents selectively direct to the cancer cells.
Graphene oxide is the water-soluble derivative of the nanoscale element graphene. Graphene oxide can readily enter or attach to the surface of cells due to its stability in water, making it the ideal medium for targeted drug delivery.
Hong Kong Yuanhua Biotechnology has developed a Graphene oxide formulation which inhibits lung cancer sphere-forming cells, forcing them to differentiate into non-CSCs, resulting in:
- Higher affinity and specificity;
Lower effective dose.
Fewer unpleasant side effects.
Less likelihood of cancer cells developing resistance to drug therapy, providing greater efficacy and better long-term treatment options.
By using the unique properties of Graphene oxide nano-particles, anti-cancer agents can concentrate on a cancer cell resulting in extremely high efficacy. Moreover, when this enhanced efficacy is accompanied by reduced uptake of anti-cancer agents by healthy cells, toxicity to normal cells is diminished, minimizing ongoing chemotherapy treatment and the unpleasant side effects it causes.
Based on our research and clinical trials, we have shown that Graphene oxide is not toxic to healthy cells when used to target drug delivery and significantly reduces common post-treatment side-effects when used as an anti-cancer therapy.
Hong Kong Yuanhua Biotechnology commitment to uncover and develop new molecules, mechanisms, and pathways for more effective cancer treatments gives the hope of providing further improved outcomes for lung cancer patients in the future.